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Abstract
Background: Even mild hyperglycemia is associated with future acute and chronic complications.
Nevertheless, many cases of diabetes in the community go unrecognized. The aim of the study was
to determine if national electronic patient records could be used to identify patients with diabetes
in a health management organization.
Methods: The central district databases of Israel's largest health management organization were
reviewed for all patients over 20 years old with a documented diagnosis of diabetes mellitus (DM)
in the chronic disease register or patient file (identified diabetic patients) or a fasting serum glucose
level of >126 mg/100 ml according to the central laboratory records (suspected diabetic patients).
The family physicians of the patients with suspected diabetes were asked for a report on their
current diabetic status.
Results: The searches yielded 1,694 suspected diabetic patients; replies from the family physicians
were received for 1,486. Of these, 575 (38.7%) were confirmed to have diabetes mellitus. Their
addition to the identified patient group raised the relative rate of diabetic patients in the district by
3.2%.
Conclusion: Cross-referencing existing databases is an efficient, low-cost method for identifying
hyperglycemic patients with unrecognized diabetes who require preventive treatment and follow-
up. This model can be used to advantage in other clinical sites in Israel and elsewhere with fully
computerized databases.
Introduction
Diabetes mellitus (DM) is a metabolic disorder character-
ized by hyperglycemia. Hyperinsulinemia and insulin
resistance herald the hyperglycemia, but are not routinely
tested. Even mild hyperglycemia, if left uncontrolled, is
associated with future micro- and macro-vascular compli-
cations [1-3]. The cluster of abnormalities that is known
as "the metabolic syndrome" is usually shared by both
diabetes type 2 patients and patients with atherosclerosis.
It includes abdominal obesity, impaired fasting glucose,
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high triglyceride levels, low high-density lipoprotein lev-
els, hypertension, elevations in low-density lipoproteins,
prothrombotic factors, and elevated free fatty acids [2].
It is essential to identify and treat every diabetic patient as
early as possible. Because of the aging of the population
and an increasing prevalence of obesity and sedentary life
habits in the Western World, the prevalence of diabetes is
increasing. However, recent studies have shown that up to
half of all cases of diabetes in the community go unrecog-
nized [4-7]. Thus, diabetes must take its place alongside
the other major risk factors as an important cause of car-
diovascular disease. In fact, it may be appropriate to say,
"diabetes is a cardiovascular disease."[2]
The purpose of this study was to describe a unique and
simple system to increase the identification of patients




Three independent databases of the Central District of
Clalit Health Services, Israel's largest HMO, were
reviewed: the centralized HMO chronic disease register,
which is based on manual reports from family practition-
ers (FPs), computerized prescription data, and hospital
discharge summaries [8]; the local internal networks of all
52 clinical in the central district containing patient records
completed by the clinics' 155 family practitioners (37%
Board-certified), all of whom had been computerizing
their files for at least 5 years; and the central HMO labora-
tory records of 1999 – 2001. Only patients older than 20
years were included. Two groups were established:
patients with a documented diagnosis of diabetes mellitus
according to one or both of the first two databases (iden-
tified diabetic patients), and patients with at least one fast-
ing serum glucose level above 126 mg/100 ml in the third
(laboratory) database who were not already classified as
diabetic patients (suspected diabetic patients). The family
physicians of the patients with suspected diabetes were
requested to report on their current diabetic status using
the guidelines of the American Diabetes Association. Data
on age, gender, and city of residence were collected as
well.
Statistical analysis
Chi-square test was used to compare non-continuous
parameters and Student's t-test and ANOVA were used to
compare continuous parameters between two groups,
respectively.
Results
The computerized search identified 19,444 hyperglycemic
patients of whom 17,750 had already been identified as
having diabetes, leaving 1,694 patients with suspected
diabetes. Replies from the FPs were received for 1486
(88% response rate). Mean age of this group was 57.0 ±
17.1 years; 57% were females. The physicians rejected a
diagnosis of DM in 911 (61.3%) of cases, and established
a diagnosis of DM in 575 cases (38.7%). Adding the newly
diagnosed patients to the identified diabetic group raised
the rate of patients with diabetes in the district by 3.2%.
Table 1 compares the demographic characteristics of the
575 newly diagnosed diabetic patients with the 911
nondiabetic patients. The "no diabetes mellitus" sub-
group showed a statistically significant female predomi-
nance (61% vs. 39%, p < 0.0001).
Figure 1 displays the distribution of women in the dia-
betic and nondiabetic subgroups as a function of age.
Below the age of 40 years, nondiabetic patients predomi-
nate, and above 50 years, diabetic patients predominate.
This uneven distribution was not demonstrated in men
(figure 2).
Neither the location of the clinic nor the Board certifica-
tion of the FPs affected the degree to which new cases of
DM were diagnosed.
Discussion
The prevalence of type 2 diabetes continues to increase in
developed countries [9,10]. The worldwide prevalence is
Table 1: Demographic characteristics of hyperglycemic patients
Newly diagnosed DM (n = 575) No DM (n = 911) p value
Age (mean ± SD) (yrs) 60.4 ± 14.6 55.3 ± 18.0 <0.0001
Males 283 (49%) 355 (39%) <0.0001
Females 292 (51%) 556 (61%)
Age of males (mean ± SD) (yrs) 60.1 ± 13.1 60.3 ± 14.6 NS
Age of females (mean ± SD) (yrs) 60.7 ± 16.1 52.1 ± 19.2 <0.0001
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expected to rise from 135 million patients in 1995 to 300
million by the year 2025 [11]. Because even mild asymp-
tomatic hyperglycemia is a risk factor for diabetic compli-
cations [1], the American Diabetes Association in 1997,
and the World Health Organization in 1999, recom-
mended lowering the diagnostic threshold for DM from a
fasting glucose level of 140 mg/100 ml to 126 mg/100 ml
[12,13].
Good glycemic control has been found to be the best pre-
ventive measure, making early detection of DM very
important. Although undiagnosed diabetic patients are
less hyperglycemic than established diabetic patients, they
still have substantial rates of diabetes-related complica-
tions and other risk factors [4,14]. In affected patients
with coronary heart disease, a significant increase in long-
term mortality has been reported [15].
Stern el al., [16] found that only 0.7% of 5,416 workers
had undiagnosed DM, a lower percentage than reported
in similar studies in other parts of the developed world [4-
7]. This difference might be explained by the mandatory
national health coverage in Israel, the easy access of
almost the entire population to primary care, and the
common practice Israeli of FPs to order fasting glucose
tests in asymptomatic patients, even in the absence of risk
factors for DM [17].
In our study, a majority of the patients with at least one
hyperglycemic reading were subsequently found not to
have DM. However, some of them could probably be clas-
sified as "prediabetic" according to criteria of the Ameri-
can Diabetes Association [18]. The Hoorn study [19]
reported that the risk of conversion to diabetes in patients
with impaired glucose tolerance (57.9/1,000 person
years) or impaired fasting glucose (51.4/1,000 person
years) during 6.5 years of follow-up was about 10 times
higher than in patients with normoglycemia (7/1,000 per-
son years). Clinical trials have shown the benefit of life-
style interventions in prediabetic patients [20,21]. This
further supports the importance of early identification of
hyperglycemic patients to both target them for lifestyle
intervention and to monitor them for conversion to DM.
The previously unrecognized diabetic patients in our
study were referred for programs for early detection of dia-
betic complications and risk factors. Some of the young
women in the suspected diabetes group who did not have
DM had a past history of gestational diabetes. This condi-
tion is a recognized risk factor for the development of
overt DM [22-24], it should be properly identified in
young women in whom transient hyperglycemia is dis-
covered, even retrospectively. In future studies it would be
very important to retrieve data and target not only patients
with fasting glucose >126 mg/dl, but also patients within
the range 110–125 mg/dl. These patients present
impaired fasting glucose levels and deserve early interven-
tion and careful follow-up.
To determine if non-Board certified FPs were less familiar
with the revised diagnostic thresholds for DM than Board-
certified FPs, we compared the rates of underdiagnosis of
DM between these two groups. No statistically significant
differences was noted. This finding may be attributable to
the in-house Education Project in DM Management intro-
duced by Clalit Health Services five years ago. Our finding
of an additional 3.2% of undiagnosed diabetic patients in
a country with an expected low rate of underdiagnosis
suggests that laboratory and clinical data should be cross-
checked routinely.
Distribution of women in the diabetic and nondiabetic sub- groups as a function of age Figure 1
Distribution of women in the diabetic and nondiabetic sub-
groups as a function of age.
Distribution of men in the diabetic and nondiabetic sub- groups as a function of age Figure 2
Distribution of men in the diabetic and nondiabetic sub-
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In summary, cross-referencing existing databases is an effi-
cient and low-cost method of identifying hyperglycemic
patients with unrecognized diabetes and patients at high
risk of DM and gestational DM, who should a targeted for
monitoring and follow-up.
This model of searching and cross-referencing clinical and
laboratory databases could be applied equally well to
many other disorders, such as hypercholesterolemia and
renal failure. It is particularly appropriate for clinical sites
with fully computerized databases, such as HMOs and
large group practices.
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